Experience of successful use of growth hormone receptor antagonist in the treatment of hereditary acromegaly as a part of McCune-Albright syndrome
AbstractAcromegaly is a severe disabling neuroendocrine disease caused by excessive production of somatotropin. Transnasal adenomectomy is a priority method of treatment. If it is impossible to perform a neurosurgical intervention, drug therapy with long-acting somatostatin analogues and radiotherapy could be recommended. These types of treatment do not always lead to the achievement of remission, especially in cases of hereditary syndromes. The study and integration into practice of additional treatment methods that allow to stop progression of the disease without side effects risks is an important goal of profile specialists.
We present a clinical case of the successful treatment with a highly selective growth hormone’s receptor antagonist Pegvisomant in a patient with a rare hereditary pathology caused by somatic mutations in the GNAS gene, McCune-Albright syndrome.
Keywords:acromegaly; McCune-Albright syndrome; somatostatin analogues; pegvisomant
Funding. The study had no sponsor support.
Conflict of interest. The author declares no conflict of interest.
For citation: Dorovskikh A.V. Experience of successful use of growth hormone receptor antagonist in the treatment of hereditary acromegaly as a part of McCune-Albright syndrome. Endokrinologiya: novosti, mneniya, obuchenie [Endocrinology: News, Opinions, Training]. 2022; 11 (3): 124–5. DOI: https://doi.org/10.33029/2304-9529-2022-11-3-124-125 (in Russian)